

of radiotherapy specifically to the site of the tumor in the bone marrow might have enhanced efficacy with the addition of bortezomib. Preclinical studies demonstrate this effect of bortezomib when combined with the bone-seeking radionuclide samarium-153 lexidronam on both human and mouse myeloma. A clinical trial using this combination to treat heavily pretreated patients with MM showed encouraging results with excellent tolerability.<sup>9</sup>

Other drugs with minimal activity as single agents for patients with MM, such as arsenic trioxide, also show chemosensitizing and radiosensitizing effects on MM cells in the laboratory, and have produced high response rates when combined with melphalan or thalidomide and steroids for previously heavily treated patients with MM.<sup>10</sup> Although histone deacetylase inhibitors show little single-agent anti-MM activity in clinical studies, these drugs have shown chemosensitizing effects in the laboratory, and early clinical results for previously treated patients with MM seem to show anti-MM effects when drugs from this new class are used in combination therapies. The treatment options for patients with MM have increased in the past year, and it is likely that the study by San Miguel *et al.* is only the beginning of a journey that will allow patients to live longer, and more fulfilled, lives with this incurable B-cell malignancy.

*Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA.*

Correspondence: Institute for Myeloma and Bone Cancer Research, Suite 300, 9201 Sunset Boulevard, West Hollywood, CA 90069, USA

[iberenson@myelomasource.org](mailto:iberenson@myelomasource.org)

doi:10.1038/nrclinonc.2009.47

#### Competing interests

The author has declared an association with the following company: Millennium Pharmaceuticals. See the article online for full details of the relationship.

1. Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials. *J. Clin. Oncol.* **16**, 3832–3842 (1998).
2. Ma, M. H. *et al.* The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. *Clin. Cancer Res.* **9**, 1136–1144 (2003).
3. Berenson, J. R. *et al.* Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. *J. Clin. Oncol.* **24**, 937–944 (2006).
4. San Miguel, J. F. *et al.* Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N. Engl. J. Med.* **359**, 906–917 (2008).
5. Reece, D. E. *et al.* Phase I–II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. *J. Clin. Oncol.* **26**, 4777–4783 (2008).
6. Pönisch, W. *et al.* Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). *J. Cancer Res. Clin. Oncol.* **132**, 205–212 (2006).
7. Orłowski, R. Z. *et al.* Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. *J. Clin. Oncol.* **25**, 3892–3901 (2007).
8. Palumbo, A. *et al.* Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. *Lancet* **367**, 825–831 (2006).
9. Berenson, J. R. *et al.* A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. *Clin. Cancer Res.* **15**, 1069–1075 (2009).
10. Berenson, J. R. *et al.* Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. *Br. J. Haematol.* **135**, 174–183 (2006).

#### IMMUNOTHERAPY

## Vaccine trials in melanoma—time for reflection

Alexander M. M. Eggermont

**The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.**

Melanoma is considered one of the most immunogenic solid tumors and the ideal candidate against which to develop various immunotherapeutic approaches. This is based on observations of spontaneous remissions, the prognostic importance of lymphocytic infiltration in primary melanomas, and responses to a variety of cytokines. Antibodies, cytokines, adoptive transfer of effector cells, immunologic preconditioning of the patient and various vaccine approaches are all of interest in the development of immunotherapeutic regimens. Overcoming various immunosuppressive conditions at the tumor site and breaking immune tolerance are probably key for further progress in this field. The complexity of orchestrating immune responses is such that success has been rather limited.

The development of an effective therapeutic vaccine for metastatic melanoma continues to be the elusive 'holy grail' in a disease where other systemic treatment approaches continue to fail. The notable exceptions at present are the adoptive immunotherapy regimens tested at the National Cancer Institute (NCI) Surgery Branch in patients with metastatic disease.<sup>1</sup> Apart from that endeavor, however, we cannot escape the very disappointing results of large, randomized, controlled trials, both in patients with stage IV melanomas, as well as in the adjuvant setting for stage II, stage III and resected stage IV disease. This situation calls for a moment of reflection.<sup>2</sup>

Rosenberg and coworkers stated that despite great advances in the field of tumor immunology in the past decades, optimism about the clinical application of currently

...we cannot escape the very disappointing results of large, randomized, controlled trials...

available cancer vaccines is based more on surrogate end points than on the observation of clinical tumor regressions.<sup>3</sup> They questioned the validity of this optimism, as well as the robustness of surrogate immunomonitoring end points. Cancer vaccine trials in 440 patients, conducted at the NCI Surgery Branch, had an overall objective response rate of only 2.6%. This result is comparable to the 4.0% response rate reported in 40 studies that involved 756 patients.<sup>3</sup> It is clear that with these very low response rates surrogate end points for tumor regression are virtually impossible to identify. Smith and colleagues, of the NCI Surgery Branch, reported that in 305 patients in whom peptide-vaccines were combined with high dose interleukin 2 (IL-2), the results were almost identical to those obtained in 379 patients treated with IL-2 alone.<sup>4</sup> Only combination of IL-2 with the immunogenic peptide gp100:209-217(210M) was associated with an increased response rate in their experience. Sosman and colleagues, however, did not observe such an increase for this peptide in three phase II trials involving 131 patients, and could only confirm the activity of high dose IL-2.<sup>5</sup>

The disappointing results in patients with advanced stage IV disease are often played down by arguments that immunosuppressed patients with stage IV disease are unsuitable for vaccine development studies, and that vaccines can probably only be successfully developed in immunocompetent patients after full resection of their tumor(s) (that is, in the adjuvant setting). However, it is precisely in this setting that large trials of adjuvant vaccines in patients with stage II–IV resected tumors have failed or, even worse, have given an indication of being potentially detrimental.

An allogeneic cancer vaccine (Canvaxin™) developed from three cell lines was used in clinical trial testing. In two large, randomized trials, 1,166 patients with stage III melanoma and 496 patients with resected stage IV melanoma were randomly allocated to receive Canvaxin™ plus *Bacillus Calmette–Guérin* (BCG) or placebo plus BCG after surgery. Both trials were closed prematurely on the advice of the Independent Data Monitoring Committee. There was a survival disadvantage in patients receiving Canvaxin™ treatment in both studies. Median survival in the stage III study had not been reached, but

the 5-year survival was 59% for those who received Canvaxin™, and 68% for untreated patients. In the stage IV study, median survival was 32 months for patients treated with Canvaxin™, and 39 months for patients who received placebo, with respective 5-year survival rates of 40% and 45%. The large phase III EORTC 18961 trial of adjuvant ganglioside vaccine GMK in 1,314 patients with stage II melanoma was stopped early by the Independent Data Monitoring Committee because of inferior survival in the vaccine treatment arm.<sup>6</sup> This difference in survival at the second interim analysis was quite similar to that observed in the second interim analysis of the ECOG1694 trial, in which 880 patients with stage IIB–III disease were randomly allocated to high-dose interferon (IFN) therapy or the GMK vaccine.<sup>7</sup> This trial is difficult to interpret with respect to the potential detrimental effect observed.<sup>2</sup> Clearly the results of these large adjuvant trials are a substantial setback to the development of a vaccination strategy in melanoma.

Results from large, randomized trials in stage IV melanoma have not indicated a turn for the better. In vaccine development, optimization of antigen presentation with dendritic cells has increased our knowledge of the mechanisms involved, but until now this has not resulted in clear advances in the clinical situation. The first large, randomized phase III trial comparing autologous peptide-pulsed dendritic cell vaccination with dacarbazine in stage IV melanoma, was closed after 108 patients had been treated. This decision was made on the basis of the interim analysis, which indicated that there were no significant differences in the response rate or overall survival between the two treatment arms.<sup>8</sup> As evaluated in a systematic review in 2008, no vaccines with proven clinical efficacy are available.

Immunesuppression mechanisms at the tumor site, and the critically important role of the tumor microenvironment, are now better understood. T-cell activation will only take place when an antigen is presented by a major histocompatibility complex molecule and a co-stimulatory molecule, B7.1 or B7.2. Binding of B7 molecules to CD28 then leads

to T-cell activation, which in turn upregulates CTLA4, which competes for binding to B7, resulting in inhibition of T-cell receptor signaling, *IL-2* gene transcription and T-cell proliferation. CTLA4 thus has a critical inhibitory role in T-cell control, and blocking this function can be a crucial step in augmenting and maintaining cytotoxic

T-cell responses, which is so desperately needed in cancer immunotherapy. The two monoclonal antibodies to CTLA4, ipilimumab and tremelimumab, can break self tolerance, and thus mediate antitumor effects; however, this can result in autoimmunity in some tissues (also

called immune-related adverse events). The antitumor effect of anti-CTLA4 antibody administration seems to be a result of increased T-cell activation, rather than inhibition or depletion of T-regulatory cells. Strikingly, in various patients with stage IV disease, slowly developing, long-lasting complete remissions have now been observed. These observations have been made both in melanoma patients with extensive metastatic disease and patients that have failed various previous treatments.

Another monoclonal antibody that has been developed acts against the programmed death 1 receptor (PD-1R), the ligand of which (PD-1L) can be directly expressed on melanoma cells. PD-1R is a part of the B7:CD28 family of co-stimulatory molecules that regulate T-cell activation and tolerance, and thus anti-PD-1R can have a role in breaking tolerance.<sup>9</sup> The antibodies, anti-OX44 and anti-1-4BB, which have an agonistic action on T-cell activation, and the anti-CD25 antibody, which targets vmx T-regulatory cells that constitutionally overexpress CD25, are examples of other potential candidates to be combined with vaccines. It has been demonstrated that combinations of these antibodies can significantly optimize T-cell responses; thus, we are probably witnessing an emerging field of immunomodulation that holds great promise.<sup>10</sup> These antibodies might be crucial to the successful development of vaccines in the future.

Rosenberg's group reported on the very impressive response rates in 93 patients with metastatic melanoma who received

...it is precisely in this setting that large trials of adjuvant vaccines ... have failed...

adoptive T-infiltrating tumor-lymphocyte therapy in combination with high dose IL-2 after myeloablative conditioning therapy with fludarabine and cyclophosphamide with or without total body irradiation. Lymphodepletion is one of the hallmarks of this innovative approach, and seems to have a crucial role in its success. Immunosuppressive lymphocyte populations in patients with advanced metastatic melanoma (that is, lymphocytes that also compete for IL-2) need to be eliminated to allow for an effective adoptive transfer of tumor-infiltrating T-cells, which can then thrive on the concomitantly administered IL-2. Competition for IL-2 by other lymphocyte populations has been reported to be able to abrogate efficacy of adoptive immune therapy.<sup>11</sup> The current approach that reported 50–72% response rates, with complete response rates of 9–16% depending on the combination with degree of total body irradiation, is of great importance. It not only demonstrates that immunotherapy has a future, but it also demonstrates that concepts such as lymphodepletion might be important for vaccine development strategies.<sup>12</sup>

It is time to pause and reassess the development of therapeutic melanoma vaccines. The potentially detrimental effects that have been observed in adjuvant trials should lead to a cautious approach, and to the development of better immune monitoring methodology. Vaccine development in stage IV disease

might require the introduction of some of the new potent and innovative immunomodulatory antibodies that considerably enhance and maintain T-cell activation. Moreover, we should be greatly encouraged by the success of the adoptive T-cell therapy with lymphodepletion approaches conducted at the NCI Surgery Branch. This approach may well contain crucial elements that could lead to eventually successful therapeutic vaccination strategies.

Department of Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus University MC, Rotterdam, The Netherlands.

Correspondence: Department of Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus University MC, 3015 EA Rotterdam, The Netherlands  
[a.eggermont@erasmusmc.nl](mailto:a.eggermont@erasmusmc.nl)

doi:10.1038/nrclinonc.2009.42

#### Competing interests

The author has declared an association with the following organization: Schering–Plough Research Institute. See the article online for full details of the relationship.

1. Dudley, M. E. *et al.* Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J. Clin. Oncol.* **26**, 5233–5239 (2008).
2. Eggermont, A. M. & Gore, M. Randomised adjuvant trials in melanoma: surgical and systemic. *Semin. Oncol.* **34**, 509–515 (2007).
3. Rosenberg, S. A. *et al.* Cancer immunotherapy: moving beyond current vaccines. *Nat. Med.* **10**, 909–915 (2004).
4. Smith, F. O. *et al.* Treatment of metastatic melanoma using interleukin-2 alone or in

conjunction with vaccines. *Clin. Cancer Res.* **14**, 5610–5618 (2008).

5. Sosman, J. A. *et al.* Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. *J. Clin. Oncol.* **26**, 2292–2298 (2008).
6. Eggermont, A. M. *et al.* EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [Abstract]. *ASCO Meeting Abstracts* **26**, 9004 (2008).
7. Kirkwood, J. M. *et al.* High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. *J. Clin. Oncol.* **19**, 2370–2380 (2001).
8. Schadendorf, D. *et al.* Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC Study Group of the DeCOG. *Ann. Oncol.* **17**, 563–570 (2006).
9. Maker, A. *et al.* Analysis of the cellular mechanism of antitumor response and autoimmunity in patients treated with CTLA-4 blockade. *J. Immunol.* **175**, 7746–7754 (2005).
10. Gray, J. C. *et al.* Optimising anti-tumor CD8 T-cell responses using combinations of immunomodulatory antibodies. *Eur. J. Immunol.* **38**, 2499–2511 (2008).
11. Eggermont, A. M. *et al.* Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumor effects of interleukin-2. *Br. J. Cancer* **56**, 97–102 (1987).
12. Rosenberg, S. A. *et al.* Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nat. Rev. Cancer* **8**, 299–308 (2008).